The FDA’s Office of Prescription Drug Promotion (OPDP) has issued a pointed warning to ARS Pharmaceutical Operations, calling its direct-to-consumer television advertisement for Neffy (epinephrine ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . Children as young as age 10 years are able to self-administer neffy 1 mg. ARS Pharmaceuticals is also working on ...
Image source: The Motley Fool. ARS Pharmaceuticals (NASDAQ:SPRY) delivered $72.2 million in U.S. net product revenue during its first full commercial year for neffy, alongside a total revenue of $84.3 ...
neffy offers a new delivery method for epinephrine in Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada ...
Earnings call ARS Pharmaceuticals reported $8M in Q1 2025 revenue, including $7.8M from neffy, its needle-free epinephrine spray. Coverage expanded from 27% to 57% of commercial lives QoQ. Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results